The logo of Swiss drug-maker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020.The logo of Swiss drug-maker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020.
Both drugs are designed to remove forms of the protein beta amyloid from the brain, sticky plaques believed to play a major role in the disease. The field of Alzheimer’s research is littered with failure and disappointment, including for several drugs in the same class, and previous efforts to prove gantenerumab’s worth.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: